State Street SPDR S&P Biotech ETF (XBI)
| Assets | $10.92B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 68.35M |
| Dividend (ttm) | $0.57 |
| Dividend Yield | 0.35% |
| Ex-Dividend Date | Jun 22, 2026 |
| Payout Frequency | Semi-Annual |
| Payout Ratio | n/a |
| Volume | 10,313,732 |
| Open | 166.66 |
| Previous Close | 169.55 |
| Day's Range | 162.53 - 167.53 |
| 52-Week Low | 88.18 |
| 52-Week High | 169.68 |
| Beta | 0.83 |
| Holdings | 156 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
14.56% of assets| Name | Symbol | Weight |
|---|---|---|
| Twist Bioscience Corporation | TWST | 1.76% |
| Oruka Therapeutics, Inc. | ORKA | 1.61% |
| Apogee Therapeutics, Inc. | APGE | 1.55% |
| Praxis Precision Medicines, Inc. | PRAX | 1.46% |
| Kymera Therapeutics, Inc. | KYMR | 1.39% |
| Natera, Inc. | NTRA | 1.37% |
| Dianthus Therapeutics, Inc. | DNTH | 1.37% |
| Protagonist Therapeutics, Inc. | PTGX | 1.36% |
| Halozyme Therapeutics, Inc. | HALO | 1.36% |
| Revolution Medicines, Inc. | RVMD | 1.33% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 22, 2026 | $0.13809 | Jun 24, 2026 |
| Dec 22, 2025 | $0.40656 | Dec 24, 2025 |
| Sep 22, 2025 | $0.02665 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
Performance
XBI had a total return of 84.59% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.11%.
News
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Healthcare Rules State Street's Top 5 ETFs in Past Month
With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key Takea...
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out...
Market rotation is the most prevalent factor for healthcare outperformance, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss the recent performance in the healthcare sector, why sentiment has turned and much more.
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A
The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-Covid
So far in 2026, biotech deals amounted to $106 billion over 201 transactions, according to PitchBook data. That momentum in dealmaking comes despite an interest rate environment that has turned for th...
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
The biotech sector took a hit this week despite a recent spike in search activity. The SPDR S&P Biotech ETF ($XBI) and iShares Biotechnology ETF ($IBB) declined slightly, while two…
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
The SPDR S&P Biotech ETF ($XBI) is drawing fresh investor attention as analysts maintain a bullish outlook on some of its underlying holdings. The fund, which tracks an equal-weighted index…
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
Why 2026 may be a strong year for biotech stocks
Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid-cap biotech names – posting one of its strongest stretches on record. Mizu...
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Final Trades: Toast, Uber, the XLB and the XBI
The Investment Committee reveals the stocks they're watching as the market sets up for its next move.
The Fed cut rates. Biotech didn't notice.
Biotechs are instead spending their time advancing the kind of smart science that will catch the eye of cash-rich pharmaceutical companies.
Final Trades: FTAI, ETN, COWZ, XBI
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Taiwan Semi, Apple and the XBI
The Investment Committee give you their top stocks to watch for the second half.
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Trade Tracker: Joe Terranova buys more XBI
Joe Terranova, senior managing director at Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying XBI again. The committee share their health care strategy.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
Final Trades: SoFi Technologies, Clearway Energy, SPDR S&P Biotech ETF and CrowdStrike
The Investment Committee's top stock picks are in—here's what they're watching now.
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Home builders lose confidence, resort to price cuts as buyers steer clear of housing market
Builders' confidence in the housing market sank in June, the National Association of Home Builders said.
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Political pressure and persistently high interest rates have some wondering if the industry's model is broken.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Single stock picking is the only way to make money in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.